M
Masayuki Towatari
Researcher at Nagoya University
Publications - 43
Citations - 3538
Masayuki Towatari is an academic researcher from Nagoya University. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 27, co-authored 43 publications receiving 3440 citations.
Papers
More filters
Journal ArticleDOI
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.
Fumihiko Hayakawa,Masayuki Towatari,Hitoshi Kiyoi,Mitsune Tanimoto,Toshio Kitamura,H Saito,Tomoki Naoe +6 more
TL;DR: In this paper, the internal tandem duplication of the human Flt3 gene in approximately 20% of acute myeloid leukemia (AML) cases was identified, and the wild-type and the mutant FLt3 genes were transfected into two IL-3-dependent cell lines, 32D and BA/F3 cells.
Journal ArticleDOI
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
Hitoshi Kiyoi,Masayuki Towatari,Shohei Yokota,Michinari Hamaguchi,Ryuzo Ohno,Hidehiko Saito,Tomoki Naoe +6 more
TL;DR: Findings suggest that the elongation of the JM domain rather than increase of tyrosine residues causes gain-of-function of FLT3, and ITD is a novel modality of somatic mutation which activates its product.
Journal ArticleDOI
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.
TL;DR: Results suggest that the immunotherapeutic use of HDACIs may become a novel tool for treatment of AML.
Journal ArticleDOI
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Masayuki Towatari,Masamitsu Yanada,Noriko Usui,Jin Takeuchi,Isamu Sugiura,Makoto Takeuchi,Fumiharu Yagasaki,Yasukazu Kawai,Shuichi Miyawaki,Shigeki Ohtake,Itsuro Jinnai,Keitaro Matsuo,Tomoki Naoe,Ryuzo Ohno +13 more
TL;DR: Although the number of patients is small and the observation period is too short, the combination therapy is very promising and produces high-quality CR for most newly diagnosed patients with BCR-ABL-positive ALL, and provides the patients with a better chance to receive an allogeneic HSC transplant.
Journal ArticleDOI
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.
Hiroshi Kosugi,Masayuki Towatari,Sonoko Hatano,Kunio Kitamura,Hitoshi Kiyoi,T Kinoshita,Mitsune Tanimoto,Takashi Murate,K Kawashima,H Saito,Tomoki Naoe +10 more
TL;DR: HDRIs are the potent inducer or enhancer of differentiation in acute myeloid leukemia and regulate transcription in an ordered manner.